Emcure Pharmaceuticals Ltd. has announced the commercial launch of Poviztra®, a semaglutide injection for weight management, across India. Emcure is the first Indian company to exclusively distribute and commercialize this second brand of Novo Nordisk's Semaglutide injection. Poviztra® is available in a once-weekly pen device in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg. The product is priced starting at ₹8790 per month (for 4 weekly doses) and features a state-of-the-art pen device for simple and precise dosing. The semaglutide injection is supported by extensive clinical evidence and has a strong safety and efficacy profile with nearly a decade of global market presence. Poviztra® is indicated for chronic weight management in adults with obesity or overweight, along with at least one weight-related comorbid condition, and also to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals Ltd., stated that the launch is a significant step in expanding access to scientifically validated weight-management solutions, addressing India's substantial obesity crisis. Emcure aims to ensure that more patients benefit from advanced therapies like semaglutide through its strong distribution network. Emcure Pharmaceuticals Ltd. is a leading Indian pharma company headquartered in Pune, engaged in developing, manufacturing, and marketing pharmaceutical products globally. Established in 1981, it is ranked as the 13th largest pharma company in India by domestic sales.
